

GW PHARMACEUTICALS PLC

FORM 6-K (Report of Foreign Issuer)

Filed 11/03/16 for the Period Ending 11/03/16

Telephone	44 1223 266800
CIK	0001351288
Symbol	GWPH
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934

For the Month of November, 2016

Commission File Number: 001-35892

GW PHARMACEUTICALS PLC

(Translation of registrant's name into English)

Sovereign House
Vision Park
Histon
Cambridge CB24 9BZ
United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes

No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes

No

Other Events

On November 3, 2016, GW Pharmaceuticals plc (the “Company”), issued a regulatory news service (“RNS”) announcement setting forth details of the conversion by Mr. Christopher Tovey, the Company’s Chief Operating Officer and a Director of certain of his ordinary shares par value £0.001 per share (“Ordinary Shares”) into American Depositary Shares (“ADSs”). This RNS is attached as Exhibit 99.1 hereto and is incorporated by reference herein. On November 2, 2016, the Company issued an RNS with details of the conversion by Mr. Justin Gover, the Company’s Chief Executive Officer and a Director of certain of his ordinary shares into ADSs. This RNS is attached as Exhibit 99.2 hereto and is incorporated by reference herein. On November 1, 2016, the Company issued an RNS with details of the conversion by Mr. James Noble, a Director, of certain of his ordinary shares into ADSs. This RNS is attached as Exhibit 99.3 hereto and is incorporated by reference herein. On October 28, 2016, the Company issued a press release with details of the establishment by Dr Geoffrey Guy, Chairman of the Company’s Board of Directors, of a personal stock trading plan in accordance both with the guidelines established by Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the EU Market Abuse Regulation, as well as the Company’s policies with respect to insider trading. This press release is attached as Exhibit 99.4 hereto and is incorporated by reference herein. On October 28, 2016 the Company issued an RNS with details of sales of Ordinary Shares by Dr Geoffrey Guy, Chairman of the Company’s Board of Directors. This RNS is attached as Exhibit 99.5 hereto and is incorporated by reference herein. The information contained in Exhibits 99.1, 99.2, 99.3, 99.4 and 99.5 hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

Exhibits

99.1	Regulatory news service announcement dated November 3, 2016 regarding Mr. Christopher Tovey
99.2	Regulatory news service announcement dated November 2, 2016 regarding Mr. Justin Gover
99.3	Regulatory news service announcement dated November 1, 2016 regarding Mr. James Noble
99.4	Press Release dated October 28, 2016 regarding Director Stock Trading Plan
99.5	Regulatory news service announcement dated October 28, 2016 regarding Dr Geoffrey Guy

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GW Pharmaceuticals plc

By: /s/ Adam George
Name: Adam George
Title: Chief Financial Officer

Date: November 3, 2016

**Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them**

1.	Details of the person discharging managerial responsibilities / person closely associated			
a.	Name	Mr Christopher Tovey		
2.	Reason for the notification			
a.	Position/status	Director/Chief Operating Officer		
b.	Initial notification /Amendment	Initial notification		
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a.	Name	GW Pharmaceuticals PLC		
b.	LEI			
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 0.1p each ISIN: GB0030544687 Restricted American Depositary Shares: ISIN: US36197T1372		
b.	Nature of the transaction	Conversion of 2,496 Ordinary shares into 208 Nasdaq listed Restricted ADRs (12 to 1 Conversion ratio)		
c.	Price(s) and volume(s)	Price(s) -	Volume(s) 208	ADs issued upon conversion of 2,496 Ordinary shares
d.	Aggregated information • <i>Aggregated volume</i> • <i>Price</i>	n/a		
e.	Date of the transaction	1 November 2016		
f.	Place of the transaction	New York		

**Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them**

1.	Details of the person discharging managerial responsibilities / person closely associated			
a.	Name	Mr Justin Gover/Gover Family Investment LLP		
2.	Reason for the notification			
a.	Position/status	Chief Executive Officer		
b.	Initial notification /Amendment	Initial notification		
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a.	Name	GW Pharmaceuticals PLC		
b.	LEI			
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 0.1p each ISIN: GB0030544687 Restricted American Depositary Shares: ISIN: US36197T1372		
b.	Nature of the transaction	Conversion of 2,513,748 Ordinary shares into 209,479 Nasdaq listed Restricted ADRs (12 to 1 Conversion ratio)		
c.	Price(s) and volume(s)	Price(s)	Volume(s)	
		-	209,479	ADSs issued upon conversion of 2,513,748 Ordinary shares
d.	Aggregated information • <i>Aggregated volume</i> • <i>Price</i>	n/a		
e.	Date of the transaction	2 November 2016		
f.	Place of the transaction	New York		

**Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them**

1.	Details of the person discharging managerial responsibilities / person closely associated			
a.	Name	Mr James Noble		
2.	Reason for the notification			
a.	Position/status	non-executive Director/Deputy Chairman		
b.	Initial notification /Amendment	Initial notification		
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a.	Name	GW Pharmaceuticals PLC		
b.	LEI			
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 0.1p each ISIN: GB0030544687 Restricted American Depositary Shares: ISIN: US36197T1372		
b.	Nature of the transaction	Conversion of 27,492 Ordinary shares into 2,291 Nasdaq listed Restricted ADRs (12 to 1 Conversion ratio)		
c.	Price(s) and volume(s)	Price(s) -	Volume(s) 2,291	ADs issued upon conversion of 27,492 Ordinary shares
d.	Aggregated information • <i>Aggregated volume</i> • <i>Price</i>	n/a		
e.	Date of the transaction	31 October 2016		
f.	Place of the transaction	New York		

Director Stock Trading Plan

London, UK; 28 October 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: "GWP," "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, has today been notified that Dr Geoffrey Guy, Chairman of the Board, has established a personal stock trading plan in accordance both with the guidelines established by Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the EU Market Abuse Regulation, as well as the Company's policies with respect to insider sales.

Rule 10b5-1 plans permit directors, officers and other company insiders to adopt, at times when they are not in possession of material, non-public information, written plans for trading securities in a non-discretionary, pre-scheduled manner in the future. These pre-planned trades can then be executed at a later date, as spelled out in the plan, without further action by the director, officer or other company insider and without regard to any subsequent non-public information the individual might have received.

Dr Guy's plan provides for the exercise and sale of options over up to 440,388 Ordinary 0.1p Shares (equivalent to 36,699 American Depository Shares), between 9 December 2016 and 1 April 2017.

Following exercise of these options, Dr Guy will continue to hold 952,034 options over Ordinary Shares (equivalent to 79,336 ADSs) and will continue to be the beneficial owner of an additional 12,847,852 Ordinary Shares (equivalent to 1,070,654 ADSs).

The transactions under the plan will be disclosed publicly through Form 144 and Form 4 filings as required by the U.S. Securities and Exchange Commission, and by announcement through a Regulatory Information Service, as required by the EU Market Abuse Regulation.

For further information, please contact:

GW Pharmaceuticals PLC +44 (0)1980 557 000

Adam George, Company Secretary

Peel Hunt LLP (Nominated Adviser)

James Steel/Oliver Jackson +44 (0) 20 7418 8900

**Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them**

1.	Details of the person discharging managerial responsibilities / person closely associated			
a.	Name	Dr Geoffrey Guy		
2.	Reason for the notification			
a.	Position/status	Director/Chairman of the Board		
b.	Initial notification /Amendment	Initial notification		
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor			
a.	Name	GW Pharmaceuticals PLC		
b.	LEI			
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 0.1p each ISIN: GB0030544687		
b.	Nature of the transaction	Sale of Ordinary shares held by personal pension		
c.	Price(s) and volume(s)	Price(s) £8.08	Volume(s) 130,000	Ordinary shares sold by personal pension
d.	Aggregated information • <i>Aggregated volume</i> • <i>Price</i>	n/a		
e.	Date of the transaction	26 October 2016		
f.	Place of the transaction	London		

4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 0.1p each ISIN: GB0030544687		
b.	Nature of the transaction	Sale of Ordinary shares held by personal pension		
c.	Price(s) and volume(s)	Price(s) £8.04	Volume(s) 138,318	Ordinary shares sold by personal pension
d.	Aggregated information • <i>Aggregated volume</i> • <i>Price</i>	n/a		
e.	Date of the transaction	27 October 2016		
f.	Place of the transaction	London		
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted			
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 0.1p each ISIN: GB0030544687		
b.	Nature of the transaction	Sale of Ordinary shares held by personal pension		
c.	Price(s) and volume(s)	Price(s) £7.90	Volume(s) 31,682	Ordinary shares sold
d.	Aggregated information • <i>Aggregated volume</i> • <i>Price</i>	n/a		
e.	Date of the transaction	28 October 2016		
f.	Place of the transaction	London		